drugset / Trial / NCT07223567
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective single-center, single-arm, open-label, phase II study evaluating the safety, activity, and efficacy of regorafenib in combination with lorigerlimab for the treatment of patients with regrowing or locally recurrent pMMR/MSS localized rectal cancer following TNT.
Timeline
- Start
- 2025-10-27
- Primary completion
- 2026-01-22
- Completion
- 2026-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorigerlimab | Protein / enzyme biologic | 6 mg/kg | Intravenous |
| Subject | Regorafenib | Small molecule | 90 mg | Oral |